Close Menu

NEW YORK – Under a new National Institutes of Health grant issued last month, researchers at the University of California, Los Angeles aim to apply a technology called "electrochemical liquid biopsy" (eLB) to predict high-risk pregnancies. 

Awarded $600,000 for the first year of the grant, the researchers hope to eventually develop a point-of-care assay that can detect the risk of conditions during pregnancy before their symptoms occur, which they believe might allow for timely interventions and eliminate placenta-related disorders.  

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.